CTNM
HEALTHCAREContineum Therapeutics Inc - Class A
$14.94+0.55 (+3.82%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CTNM Today?
No stock-specific AI insight has been generated for CTNM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.35$16.33
$14.94
Fundamentals
Market Cap$559M
P/E Ratio—
EPS$-1.94
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume243K
Avg Volume (10D)—
Shares Outstanding32.7M
CTNM News
20 articles- Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a BetYahoo Finance·May 8, 2026
- Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development MilestonesYahoo Finance·May 5, 2026
- Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 1, 2026
- Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic PainYahoo Finance·Apr 30, 2026
- We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business GrowthYahoo Finance·Apr 19, 2026
- Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink ConferenceMarketbeat·Mar 15, 2026
- Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 13, 2026
- Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development MilestonesYahoo Finance·Mar 5, 2026
- Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare ConferenceYahoo Finance·Mar 3, 2026
- Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in FocusYahoo Finance·Mar 2, 2026
- Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Feb 4, 2026
- Contineum Therapeutics, Inc. (NASDAQ:CTNM) surges 10%; retail investors who own 51% shares profited along with institutionsYahoo Finance·Jan 27, 2026
- Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock?Yahoo Finance·Dec 31, 2025
- Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?Yahoo Finance·Dec 31, 2025
- Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public OfferingYahoo Finance·Dec 12, 2025
- Contineum Therapeutics Announces Proposed $75.0 Million Public OfferingYahoo Finance·Dec 11, 2025
- Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare ConferenceYahoo Finance·Nov 24, 2025
- A brain biotech’s top drug fails against MSBiopharmadive·Nov 21, 2025
- Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)Yahoo Finance·Nov 20, 2025
- Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development MilestonesYahoo Finance·Oct 30, 2025
All 20 articles loaded
Price Data
Open$14.49
Previous Close$14.39
Day High$15.66
Day Low$14.34
52 Week High$16.33
52 Week Low$3.35
52-Week Range
$3.35$16.33
$14.94
Fundamentals
Market Cap$559M
P/E Ratio—
EPS$-1.94
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume243K
Avg Volume (10D)—
Shares Outstanding32.7M
About Contineum Therapeutics Inc - Class A
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—